Jeffrey L. Cummings, MD, ScD, The University of Nevada, Reno, NV, discusses the value of Phase II trials in Alzheimer’s disease (AD) drug development and how these trials should be approached in the future. It is believed that exploratory trials should be conducted that help us to learn more about a compound before moving on to Phase III clinical trials. Improving the understanding of aspects such as dosage, target engagement and biomarker outcomes could improve efficiency in clinical development. This interview took place during the AD/PD™ 2021 conference.
Dr. Cummings has provided consultation to Acadia, Alkahest, AriBio, Avanir, Axsome, Behren Therapeutics, Biogen, Cassava, Cerecin, Cerevel, Cortexyme, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, Grifols, Janssen, Jazz, Karuna, Merck, Novo Nordisk, Otsuka, ReMYND, Resverlogix, Roche, Samumed, Samus, Signant Health, Sunovion, Suven, United Neuroscience, and Unlearn AI pharmaceutical and assessment companies.